Open-label extension data confirms sustained benefit of acoramidis on cardiovascular outcomes, including statistically significant reduction in acm within 36 months

- acoramidis demonstrated the earliest known time to separation in cardiovascular outcomes in the attribute-cm study (3 months), with statistically significant risk reduction of 36% on all-cause mortality (acm) alone at month 36 within the open label extension
ACM Ratings Summary
ACM Quant Ranking